Karen Young

Memory, Roche Craft CNS Deal With Potential Value Of $150M

July 31, 2002

Memory Pharmaceuticals Corp., a company focused on neurodegenerative diseases, secured its first licensing agreement, a potential $150 million deal with F. Hoffmann-La Roche Ltd. focused on the development of compounds for Alzheimer's disease. (BioWorld Today)

BioTransplant Cuts Work Force As Part Of Conservation Plan

July 31, 2002

By Karen Young

BioTransplant Cuts Work Force As Part Of Conservation Plan

July 31, 2002

By Karen Young

Memory, Roche Craft CNS Deal With Potential Value Of $150M

July 31, 2002

By Karen Young

Memory Pharmaceuticals Corp., a company focused on neurodegenerative diseases, secured its first licensing agreement, a potential $150 million deal with F. Hoffmann-La Roche Ltd. focused on the development of compounds for Alzheimer's disease. (BioWorld Today)